Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 12/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5472324 | 0.85 | IGF1R (0.47) | IGF1RL3MBTL1TAS2R8PPARGPPARD | |
| Trifluoroacetic Acid SCHEMBL4887644 | 0.80 | IGF1R (0.51) | IGF1RTAS2R8PPARGPPARDPPARA | |
| Trifluoroacetic Acid SCHEMBL4884663 | 0.78 | IGF1R (0.61) | IGF1RPPARGPPARDPPARA | |
| SCHEMBL5478685 | 0.73 | KDM4E (0.32) | L3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL3723113 | 0.73 | IGF1R (0.48) | IGF1RPPARGPPARDPPARA | |
| Trifluoroacetic Acid SCHEMBL3730837 | 0.72 | IGF1R (0.72) | IGF1RPPARGPPARDPPARA | |
| Trifluoroacetic Acid SCHEMBL1130222 | 0.71 | IGF1R (0.44) | IGF1RL3MBTL1PPARGPPARDPPARA | |
| Trifluoroacetic Acid SCHEMBL4886037 | 0.71 | IGF1R (0.62) | IGF1RTAS2R8PPARGPPARDPPARA | |
| Trifluoroacetic Acid SCHEMBL4879669 | 0.70 | IGF1R (0.61) | IGF1RTAS2R8PPARGPPARDPPARA | |
| Trifluoroacetic Acid SCHEMBL4884577 | 0.70 | IGF1R (0.61) | IGF1RTAS2R8PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259891-A1 | Heterocycle-Substituted Cyclic Urea Derivatives, Preparation Thereof And Pharmaceutical Use Thereof As Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2007-11-08 | — | — | US | disclosed |
| EP-1621539-A1 | Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | Aventis Pharma S.A. (FR) | 2006-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259891-A1 | Heterocycle-Substituted Cyclic Urea Derivatives, Preparation Thereof And Pharmaceutical Use Thereof As Kinase Inhibitors | CDK1, PRKAR2B, MAP3K19 | IGF1R 854/4885L3MBTL1 4062/4885TAS2R8 3001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.